Cancer News and Research

Latest Cancer News and Research

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.

23 Nov 2009

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

A Loyola University Health System study has found that one out of five Type 2 diabetics is morbidly obese -- approximately 100 pounds or more overweight.

23 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

Guideline controversy: 'Politics is always intruding into the world of breast cancer'

Kaiser Health News' Peggy Girshman talks with Dr. Barron Lerner about the politics surrounding the recent release of mammography guidelines.

23 Nov 2009

Administration seeks to distance reform effort from cancer screening fallout

As the intense debate continues over new cancer test guidelines, the Obama administration is trying to protect health care reform from the controversy's fallout.

23 Nov 2009

Urodynamix Technologies announces the publication of AMA's 2010 Current Procedural Terminology

Urodynamix Technologies Ltd. today announced that the American Medical Association (AMA) has published its 2010 Current Procedural Terminology (CPT) codes with additions, changes and deletions of billing codes for all medical specialities including urology.

23 Nov 2009

Alcohol consumption in pregnancy affects child behaviour in different ways: Study

A new study from Perth's Telethon Institute for Child Health Research has found evidence that the amount and timing of alcohol consumption in pregnancy affects child behaviour in different ways.

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

OncoVista Innovative Therapies, Inc., reported that the AdnaTest BreastCancer Select & Detect kit, manufactured by AdnaGen AG (Langenhagen, Germany), is now available for research as well as for pay-out-of-pocket patients in the Czech Republic and Slovakia.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Nevada Cancer Institute has selected Sprint as its wireless communications provider of choice at its new, state-of-the-art facility near Las Vegas. This is the first Sprint in-building coverage and capacity agreement involving a large healthcare institution in the Las Vegas market.

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Marriott UMUC's initiative to collect funds for Children’s Miracle Network

Armed with $5 bills, the shoppers lined up waiting for the doors to open. Sound like some kind of bizarre sale? This was no sale, it was the scene at the opening of the temporary thrift store at Marriott’s University of Maryland University College Inn and Conference Center. Local community members in need were invited to stuff as many clothes as they could into shopping bags for $5 a bag. All proceeds went to the Children’s Miracle Network (CMN).

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

First Edition: November 23, 2009

Today's headlines indicate that even after Senate Majority Leader Harry Reid found victory Saturday night with the first health bill test vote, his measure is likely to be the subject of an even more intense debate as the measure moves forward.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

Mutated IDH1 gene linked to the progression of gliomas

Guideline controversy: 'Politics is always intruding into the world of breast cancer'

Administration seeks to distance reform effort from cancer screening fallout

Urodynamix Technologies announces the publication of AMA's 2010 Current Procedural Terminology

Alcohol consumption in pregnancy affects child behaviour in different ways: Study

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Marriott UMUC's initiative to collect funds for Children’s Miracle Network

Kingston University receives £99,000 for cancer research

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

First Edition: November 23, 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in